110 related articles for article (PubMed ID: 19609198)
1. The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells.
Shehu-Xhilaga M; Rhodes D; Wightman F; Liu HB; Solomon A; Saleh S; Dear AE; Cameron PU; Lewin SR
AIDS; 2009 Sep; 23(15):2047-50. PubMed ID: 19609198
[TBL] [Abstract][Full Text] [Related]
2. Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1.
Choi BS; Lee HS; Oh YT; Hyun YL; Ro S; Kim SS; Hong KJ
AIDS; 2010 Feb; 24(4):609-11. PubMed ID: 20154582
[TBL] [Abstract][Full Text] [Related]
3. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation.
Williams SA; Chen LF; Kwon H; Ruiz-Jarabo CM; Verdin E; Greene WC
EMBO J; 2006 Jan; 25(1):139-49. PubMed ID: 16319923
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 reactivation induced by apicidin involves histone modification in latently infected cells.
Lin S; Zhang Y; Ying H; Zhu H
Curr HIV Res; 2011 Jun; 9(4):202-8. PubMed ID: 21631428
[TBL] [Abstract][Full Text] [Related]
5. Novel histone deacetylase inhibitor NCH-51 activates latent HIV-1 gene expression.
Victoriano AF; Imai K; Togami H; Ueno T; Asamitsu K; Suzuki T; Miyata N; Ochiai K; Okamoto T
FEBS Lett; 2011 Apr; 585(7):1103-11. PubMed ID: 21402072
[TBL] [Abstract][Full Text] [Related]
6. Chromatin-associated regulation of HIV-1 transcription: implications for the development of therapeutic strategies.
Quivy V; De Walque S; Van Lint C
Subcell Biochem; 2007; 41():371-96. PubMed ID: 17484137
[TBL] [Abstract][Full Text] [Related]
7. Histonedeacetylase inhibitor Oxamflatin increase HIV-1 transcription by inducing histone modification in latently infected cells.
Yin H; Zhang Y; Zhou X; Zhu H
Mol Biol Rep; 2011 Nov; 38(8):5071-8. PubMed ID: 21181272
[TBL] [Abstract][Full Text] [Related]
8. Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: Potent inhibition of histone deacetylases.
Gu W; Nusinzon I; Smith RD; Horvath CM; Silverman RB
Bioorg Med Chem; 2006 May; 14(10):3320-9. PubMed ID: 16434199
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O
Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270
[TBL] [Abstract][Full Text] [Related]
10. Differential protein acetylation induced by novel histone deacetylase inhibitors.
Glaser KB; Li J; Pease LJ; Staver MJ; Marcotte PA; Guo J; Frey RR; Garland RB; Heyman HR; Wada CK; Vasudevan A; Michaelides MR; Davidsen SK; Curtin ML
Biochem Biophys Res Commun; 2004 Dec; 325(3):683-90. PubMed ID: 15541343
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 protease inhibitors do not interfere with provirus transcription and host cell apoptosis induced by combined treatment TNF-alpha + TSA.
Vandergeeten C; Quivy V; Moutschen M; Van Lint C; Piette J; Legrand-Poels S
Biochem Pharmacol; 2007 Jun; 73(11):1738-48. PubMed ID: 17386923
[TBL] [Abstract][Full Text] [Related]
12. A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways.
Hwang JJ; Kim YS; Kim MJ; Jang S; Lee JH; Choi J; Ro S; Hyun YL; Lee JS; Kim CS
Anticancer Drugs; 2009 Oct; 20(9):815-21. PubMed ID: 19644355
[TBL] [Abstract][Full Text] [Related]
13. Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor beta Type II receptor expression in human pancreatic cancer cells.
Zhao S; Venkatasubbarao K; Li S; Freeman JW
Cancer Res; 2003 May; 63(10):2624-30. PubMed ID: 12750289
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells.
Huber K; Doyon G; Plaks J; Fyne E; Mellors JW; Sluis-Cremer N
J Biol Chem; 2011 Jun; 286(25):22211-8. PubMed ID: 21531716
[TBL] [Abstract][Full Text] [Related]
15. Reactivation of latent HIV by histone deacetylase inhibitors.
Shirakawa K; Chavez L; Hakre S; Calvanese V; Verdin E
Trends Microbiol; 2013 Jun; 21(6):277-85. PubMed ID: 23517573
[TBL] [Abstract][Full Text] [Related]
16. Thiol-based SAHA analogues as potent histone deacetylase inhibitors.
Suzuki T; Kouketsu A; Matsuura A; Kohara A; Ninomiya S; Kohda K; Miyata N
Bioorg Med Chem Lett; 2004 Jun; 14(12):3313-7. PubMed ID: 15149697
[TBL] [Abstract][Full Text] [Related]
17. Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation.
Rasmussen TA; Schmeltz Søgaard O; Brinkmann C; Wightman F; Lewin SR; Melchjorsen J; Dinarello C; Østergaard L; Tolstrup M
Hum Vaccin Immunother; 2013 May; 9(5):993-1001. PubMed ID: 23370291
[TBL] [Abstract][Full Text] [Related]
18. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges.
Atadja P
Cancer Lett; 2009 Aug; 280(2):233-41. PubMed ID: 19344997
[TBL] [Abstract][Full Text] [Related]
19. Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors.
Ylisastigui L; Coull JJ; Rucker VC; Melander C; Bosch RJ; Brodie SJ; Corey L; Sodora DL; Dervan PB; Margolis DM
J Infect Dis; 2004 Oct; 190(8):1429-37. PubMed ID: 15378435
[TBL] [Abstract][Full Text] [Related]
20. Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1.
Martínez-Bonet M; Clemente MI; Serramía MJ; Muñoz E; Moreno S; Muñoz-Fernández MÁ
Sci Rep; 2015 Nov; 5():16445. PubMed ID: 26563568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
